{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:06:40Z","timestamp":1791893200831,"version":"4.3.4"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s11060-022-03989-7","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T10:07:08Z","timestamp":1649671628000},"page":"457-463","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Quantifying intraventricular drug delivery utilizing programmable ventriculoperitoneal shunts as the intraventricular access device"],"prefix":"10.1007","volume":"157","author":[{"given":"Sheila S.","family":"McThenia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeta","family":"Pandit-Taskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Grkovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Donzelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safiatu","family":"Diagana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey P.","family":"Greenfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M.","family":"Souweidane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3803-878X","authenticated-orcid":false,"given":"Kim","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,11]]},"reference":[{"key":"3989_CR1","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3389\/fonc.2020.00739","volume":"10","author":"E Belykh","year":"2020","unstructured":"Belykh E, Shaffer KV, Lin C, Byvaltsev VA, Preul MC, Chen L (2020) Blood-brain barrier, blood-brain tumor barrier, and fluorescence-guided neurosurgical oncology: delivering optical labels to brain tumors. Front Oncol 10:739. https:\/\/doi.org\/10.3389\/fonc.2020.00739","journal-title":"Front Oncol"},{"issue":"1","key":"3989_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","volume":"2","author":"WM Pardridge","year":"2005","unstructured":"Pardridge WM (2005) The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2(1):3\u201314. https:\/\/doi.org\/10.1602\/neurorx.2.1.3","journal-title":"NeuroRx"},{"issue":"8","key":"3989_CR3","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3390\/jcm7080216","volume":"7","author":"MC Burger","year":"2018","unstructured":"Burger MC, Wagner M, Franz K, Harter PN, Bahr O, Steinbach JP, Senft C (2018) Ventriculoperitoneal shunts equipped with on-off values for intraventricular therapies in patients with communicating hydrocephalus due to leptomeningeal metastases. J Clin Med 7(8):216. https:\/\/doi.org\/10.3390\/jcm7080216","journal-title":"J Clin Med"},{"key":"3989_CR4","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.2147\/IJN.S231479","volume":"15","author":"C Ferraris","year":"2020","unstructured":"Ferraris C, Cavalli R, Panciani PP, Battaglia L (2020) Overcoming the blood-brain barrier: successes and challenges in developing nanoparticle-mediated drug delivery systems for the treatment of brain tumours. Int J Nanomedicine 15:2999\u20133022. https:\/\/doi.org\/10.2147\/IJN.S231479","journal-title":"Int J Nanomedicine"},{"issue":"9","key":"3989_CR5","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.2174\/1381612822666151221150733","volume":"22","author":"DS Hersh","year":"2016","unstructured":"Hersh DS, Wadajkar AS, Roberts N, Perez JG, Connolly NP, Frenkel V, Winkles JA, Woodworth GF, Kim AJ (2016) Evolving drug delivery strategies to overcome the blood brain barrier. Curr Pharm Des 22(9):1177\u20131193. https:\/\/doi.org\/10.2174\/1381612822666151221150733","journal-title":"Curr Pharm Des"},{"issue":"6","key":"3989_CR6","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s13139-019-00618-6","volume":"53","author":"A Gholamrezanezhad","year":"2019","unstructured":"Gholamrezanezhad A, Shooli H, Jokar N, Nemati R, Assadi M (2019) Radioimmunotherapy (RIT) in brain tumors. Nucl Med Mol Imaging 53(6):374\u2013381. https:\/\/doi.org\/10.1007\/s13139-019-00618-6","journal-title":"Nucl Med Mol Imaging"},{"key":"3989_CR7","doi-asserted-by":"publisher","DOI":"10.1227\/01.NEU.0000383138.78632","author":"G Zada","year":"2010","unstructured":"Zada G, Chen TC (2010) A novel method for administering intrathecal chemotherapy in patients with leptomeningeal metastases and shunted hydrocephalus: case report. Oper Neurosurg. https:\/\/doi.org\/10.1227\/01.NEU.0000383138.78632","journal-title":"Oper Neurosurg"},{"issue":"8","key":"3989_CR8","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/S1470-2045(18)30322-X","volume":"19","author":"MM Souweidane","year":"2018","unstructured":"Souweidane MM, Kramer K, Pandit-Taskar N, Zhou Z, Haque S, Zanzonico P, Carrasquillo JA, Lyashchenko SK, Thakur SB, Donzelli M, Turner RS, Lewis JS, Cheung NKV, Larson SM, Dunkel IJ (2018) Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial. Lancet Oncol 19(8):1040\u20131050. https:\/\/doi.org\/10.1016\/S1470-2045(18)30322-X","journal-title":"Lancet Oncol"},{"issue":"1","key":"3989_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s11060-019-03139-6","volume":"143","author":"K Bailey","year":"2019","unstructured":"Bailey K, Pandit-Taskar N, Humm JL, Zanzonico P, Gilheeney S, Cheung KV, Kramer K (2019) Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes. J Neurooncol 143(1):101\u2013106. https:\/\/doi.org\/10.1007\/s11060-019-03139-6","journal-title":"J Neurooncol"},{"key":"3989_CR10","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3389\/fonc.2020.01582","volume":"10","author":"JD Patterson","year":"2020","unstructured":"Patterson JD, Henson JC, Breese RO, Bielamowicz KJ, Rodriguez A (2020) CAR T cell therapy for pediatric brain tumors. Front Oncol 10:1682","journal-title":"Front Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-022-03989-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-022-03989-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-022-03989-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T07:12:36Z","timestamp":1651734756000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-022-03989-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["3989"],"URL":"https:\/\/doi.org\/10.1007\/s11060-022-03989-7","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,11]]},"assertion":[{"value":"18 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kim Kramer discloses paid consulting for and holding equity in YmAbs Therapeutics, Inc. Kim Kramer also discloses expert testimony (Tydings) and patents pending. N. Pandit-Taskar has served as a\u00a0consultant for or been on an advisory board and has received honoraria for Actinium Pharma, Progenics, Medimmune\/Astrazeneca, Illumina, ImaginAb, and conducts research institutionally supported by Ymabs, ImaginAb, BMS, Bayer, Clarity pharma, Janssen and Regeneron. The remaining authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}